Brief: Pharmabcine Announces Submission Of PCT For An Anti-Ang2 Antibody For The Treatment Of Ocular Diseases
19/08/2021 13:21
Aug 19 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE ANNOUNCES SUBMISSION OF PERCENT FOR AN
ANTI-ANG2
ANTIBODY FOR THE TREATMENT OF OCULAR DISEASES
Source text for Eikon: ID:nPn7XSKyxa
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration